白蛋白紫杉醇联合吉西他滨与FOLFIRINOX治疗晚期胰腺癌真实世界研究的疗效评价

Real-World Comparative Effectiveness of Nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX in Advanced Pancreatic Cancer

1文献来源Chiorean EG,Cheung WY,Giordano G,et al.Real world comparative effectiveness of nab Paclitaxel plus Gemcitabine versus FOLFIRINOX in advanced pancreatic cancer:A systematic review[J].Ther Adv Med Oncol,2019 May 19;11:1758835919850367.doi:10.1177/1758835919850367.2证据水平2a。3背景晚期胰腺癌(advanced pancreatic cancer,aPC)的治疗效果不佳,5年生存率约为3%。单药吉西他滨是aPC的标准治疗方案,但已证实疗效不如联合化疗方案如白蛋白紫杉醇联合吉西他滨(nab Paclitaxel/Gemcitabine,nab P/G)与FOLFIRINOX(氟尿嘧啶+亚叶酸钙+奥沙利铂+伊立替康)。社区治疗中肿瘤科医师对瘦弱的转移性胰腺癌(metastasis pancreatic cancer,mPC)患者倾向于选用nab P/G作为一线治疗,而对年轻男性患者倾向于选用FOLFIRINOX。然而,选择nab P/G或FOLFIRINOX的依据尚不清楚。